Incidence, Predictors, and Outcomes of Implantable Cardioverter‐Defibrillator Discharge Among People Living With HIV
Raza M. Alvi(Massachusetts General Hospital), Tomas G. Neilan(Albert Einstein College of Medicine), Malek Hassan(Massachusetts General Hospital), Connor P. Mulligan(Harvard University), Magid Awadalla(Massachusetts General Hospital), Anne M. Neilan(Harvard University), Adam Rokicki(Harvard University), Maryam Afshar(Bronx-Lebanon Hospital Center), Markella V. Zanni(Harvard University), Noor Tariq(Yale New Haven Hospital), Virginia A. Triant(Brigham and Women's Hospital)
Cited by 12
Related Papers
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
|The Journal of Clinical Endocrinology & Metabolism|2007|1.6k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589